Kinney Drugs’ pharmacists address compliance issues
GOUVERNEUR, N.Y. October is American Pharmacists Month, and Kinney Drugs has spent it educating patients about the medicines they take and how a relationship with their pharmacist can ensure the safety and efficacy of their therapies, the regional chain said Tuesday.
Poor medication adherence is estimated to cost the healthcare system $290 billion a year, according to the New England Healthcare Institute, while healthcare market research firm IMS Health estimated that only 25% to 30% of new prescriptions are properly taken.
“Compliance is driven by access and affordability, and it’s easy to be noncompliant when people have to make purchasing decisions, they can’t get to the pharmacy or they are not fully informed about their medication,” Kinney Drugs pharmacy director Mike Duteau said. “Pharmacists can make it easier for people to understand their health care and the value of taking medications as prescribed by their doctors.”
The company is highlighting some of the programs it offers, such as e-prescribing, prescription discount plans, automatic refills, flu immunizations and free Medicare Part D consultations. Kinney will sponsor a Community Medicine Take Back event on Wednesday, designed to help customers dispose of medications in a safe and environmentally sound way.
Teva, Sandoz launch Prevacid SoluTab generics
JERUSALEM The Food and Drug Administration granted approval for Teva’s abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers.
The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data.
Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.
FDA OKs expanded use of Baraclude
PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.
Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.
“This additional indication for Baraclude is important news as it is now proven to be an effective treatment option for physicians to help in managing chronic hepatitis B patients with decompensated liver disease,” University of Hawaii professor of medicine Naoky Tsai said.